Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

Keyphrases

• Src Kinase Inhibitor 100%
• Imatinib Mesylate 100%
• BCR-ABL 100%
• Imatinib 60%
• Overexpressing 40%
• Chronic Myeloid Leukemia 40%
• Pyrimidine 40%
• Pyrido 40%
• Cell Death 20%
• Oncoprotein 20%
• Kinase Activity 20%
• Murine Cells 20%
• Monotherapy 20%
• Multiple Mechanisms 20%
• Src Kinase 20%
• Leukemic Cells 20%
• Drug Class 20%
• Kinase Domain 20%
• Resistance to Imatinib 20%
• Refractoriness 20%
• Structural Difference 20%
• Resistant Cells 20%
• Clinical Resistance 20%
• Imatinib Therapy 20%
• Myeloid Leukemia Cells 20%
• Abl Kinase 20%
• Imatinib Resistance 20%
• Cell Line Models 20%
• T315I mutation 20%
• Molecular Contacts 20%

Biochemistry, Genetics and Molecular Biology

• Src Family Kinase 100%
• Imatinib 100%
• Myeloid 25%
• Cell Death 12%
• Kinase 12%
• Phosphotransferase 12%